Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Single Dose Study to Evaluate the Safety and Tolerability of ER-100 in Optic Neuropathies [Open Angle Glaucoma (OAG) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)]

NCT07290244 is registered in ClinicalTrials.gov with Life Biosciences Inc. as lead sponsor.

NCT NCT07290244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07290244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Single Dose Study to Evaluate the Safety and Tolerability of ER-100 in Optic Neuropathies [Open Angle Glaucoma (OAG) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)]
Lead sponsor
Life Biosciences Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 2, 2026
Completion date
March 31, 2032
Enrollment
18 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

naion( non-arteritic anterior ischemic optic neuropathy), open angle glaucoma (oag)